Analysts See $1.68 EPS for Quest Diagnostics Incorporated (DGX)

September 25, 2018 - By Brian Ramirez

Quest Diagnostics Incorporated (NYSE:DGX) LogoInvestors sentiment increased to 0.93 in Q2 2018. Its up 0.13, from 0.8 in 2018Q1. It increased, as 30 investors sold Quest Diagnostics Incorporated shares while 204 reduced holdings. 72 funds opened positions while 145 raised stakes. 110.90 million shares or 0.82% less from 111.81 million shares in 2018Q1 were reported.
Wedge Mgmt L L P Nc reported 13,435 shares or 0.01% of all its holdings. Millennium Mngmt Llc invested 0.05% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Hm Payson And invested 0.05% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Heartland Advsr stated it has 0.55% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Citigroup, a New York-based fund reported 208,196 shares. Fiduciary reported 3,673 shares or 0.01% of all its holdings. Hillsdale holds 60 shares or 0% of its portfolio. First Republic Invest Mngmt Inc has 7,060 shares. Laurion Mngmt Limited Partnership owns 3,200 shares for 0% of their portfolio. Alyeska Inv Grp Incorporated Lp, a Illinois-based fund reported 742,632 shares. Bp Public Limited Co stated it has 0.06% of its portfolio in Quest Diagnostics Incorporated (NYSE:DGX). Vanguard Gp Inc stated it has 0.07% in Quest Diagnostics Incorporated (NYSE:DGX). Toronto Dominion Fincl Bank reported 87,855 shares stake. Cibc Asset Management Incorporated reported 0.01% stake. Virginia Retirement Et Al owns 48,700 shares for 0.07% of their portfolio.

Since May 25, 2018, it had 0 insider purchases, and 6 selling transactions for $40.17 million activity. $18.03M worth of Quest Diagnostics Incorporated (NYSE:DGX) shares were sold by RUSCKOWSKI STEPHEN H. $173,623 worth of Quest Diagnostics Incorporated (NYSE:DGX) shares were sold by LEIDEN JEFFREY M. PREVOZNIK MICHAEL E had sold 30,780 shares worth $3.48 million. Another trade for 61,533 shares valued at $6.50M was made by GUINAN MARK on Friday, May 25.

Analysts expect Quest Diagnostics Incorporated (NYSE:DGX) to report $1.68 EPS on October, 18.They anticipate $0.29 EPS change or 20.86 % from last quarter’s $1.39 EPS. DGX’s profit would be $229.60 million giving it 16.01 P/E if the $1.68 EPS is correct. After having $1.75 EPS previously, Quest Diagnostics Incorporated’s analysts see -4.00 % EPS growth. The stock decreased 0.02% or $0.02 during the last trading session, reaching $107.59. About 1.35 million shares traded or 55.51% up from the average. Quest Diagnostics Incorporated (NYSE:DGX) has risen 0.34% since September 25, 2017 and is uptrending. It has underperformed by 15.28% the S&P500.

Quest Diagnostics Incorporated (NYSE:DGX) Ratings Coverage

Among 10 analysts covering Quest Diagnostics (NYSE:DGX), 8 have Buy rating, 0 Sell and 2 Hold. Therefore 80% are positive. Quest Diagnostics had 10 analyst reports since May 1, 2018 according to SRatingsIntel. The stock of Quest Diagnostics Incorporated (NYSE:DGX) has “Outperform” rating given on Tuesday, May 1 by Robert W. Baird. On Friday, May 25 the stock rating was maintained by Mizuho with “Buy”. The rating was maintained by Credit Suisse on Friday, May 25 with “Outperform”. On Friday, June 8 the stock rating was upgraded by William Blair to “Buy”. The firm earned “Outperform” rating on Tuesday, July 10 by Evercore. Deutsche Bank downgraded the stock to “Hold” rating in Wednesday, June 27 report. The firm has “Overweight” rating by Morgan Stanley given on Tuesday, May 29. Argus Research maintained it with “Buy” rating and $120 target in Friday, September 14 report. As per Monday, June 25, the company rating was upgraded by Barclays Capital.

Quest Diagnostics Incorporated provides diagnostic testing information and services in the United States and internationally. The company has market cap of $14.70 billion. The companyÂ’s Diagnostic Information Services business segment develops and delivers diagnostic testing information and services, such as routine testing, gene and esoteric testing, and drugs-of-abuse testing, as well as anatomic pathology services, and related services and insights. It has a 18.52 P/E ratio. This segment offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Focus Diagnostics, Athena Diagnostics, ExamOne, Quanum, and Care360 brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, and phlebotomists in physician offices.

Another recent and important Quest Diagnostics Incorporated (NYSE:DGX) news was published by Seekingalpha.com which published an article titled: “Quest Diagnostics acquires ReproSource” on September 24, 2018.

Quest Diagnostics Incorporated (NYSE:DGX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.